Cellares raises $277 million in its Series D round, with ARK Invest contributing $20 million. The funding will support advancements in cell therapy manufacturing.
PRIVATEJun 09, 2026
Amount Raised
$277 Million
Round Type
Series D
South San FranciscoManufacturingBiotechnology
Investors
BlackrockWillett AdvisorsDFJ GrowthDC Global VenturesGates FrontierEdbiIntuitive VenturesDuquesne Family OfficeBaillie GiffordT. Rowe Price Investment Management, Inc.EclipseARK Invest
Description
Cellares has secured $277 million in its Series D financing, including a $20 million investment from ARK Invest. The funds will be used to enhance cell therapy manufacturing capabilities and support commercial-scale operations. Cellares is focused on transforming the manufacturing process with automation and innovation. This funding comes as the company signs a 10-year supply agreement with Cabaletta Bio and delivers its first doses to patients.
Who to call at Cellares, and when
A new round usually means Cellares is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Cellares raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Cellares, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cellares. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Cellares
Location
345 ALLERTON AVE
South San Francisco, California, United States
About
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cellares raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoManufacturingBiotechnology